BiondVax Pharmaceuticals Ltd. BVXV

$ 1.36 0.74%

Annual report 2021
added 12-23-2023

BiondVax Pharmaceuticals Ltd. Income Statement 2011-2024 | BVXV

Annual Income Statement BiondVax Pharmaceuticals Ltd.

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	740 M	50.4 M	89.3 M	34.5 M	36.5 M	15.9 M	9.5 M	-	-	-	-
Shares	565 M	11.1 M	8.17 M	6.54 M	5.03 M	3.38 M	2.64 M	-	-	-	-
Historical Prices	1.31	4.55	10.9	5.28	7.26	5.05	3.6	-	-	-	-
Net Income	-40 M	-4.46 M	-109 M	-87.7 M	-34.6 M	-9.18 M	-10.2 M	-7.76 M	-8.04 M	-9.33 M	-7.72 M
Revenue	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-11.9 M	-11.2 M	-7.46 M	-6.93 M	-8.4 M	-7.62 M
Operating Expenses	-	-	78.4 M	77.1 M	23.7 M	11.9 M	11.3 M	8.14 M	-	-	-
General and Administrative Expenses	24.5 M	16.1 M	9.35 M	5.09 M	4.75 M	4.06 M	3.26 M	2.65 M	-	-	-

All numbers in ILS currency

Quarterly Income Statement BiondVax Pharmaceuticals Ltd.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	-	-	-	-	-	573 M	-	-	-	538 M	433 M	-	-	-	261 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-9.05 M	-	-	-	55.3 M	-42 M	-	-	-19.4 M	-47.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	16.1 M	-	-	-	19.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	-	-	-	-	-	6.2 M	-	-	-	7.3 M	4.14 M	-	-	2.79 M	4.52 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in ILS currency